Key Highlights

● Geron discontinued a late-stage clinical trial.

● An independent monitoring committee advised it was unlikely to succeed.

● The decision followed a review for overall survival benefit.

● Geron's approved drug Rytelo remains its main revenue source.

Geron (NASDAQ:GERN) sank after the biotech said it would discontinue a late-stage clinical trial. The decision followed advice from the trial's independent data monitoring committee, which said the study was unlikely to meet its overall survival endpoint, according to a market review citing a company filing.

Stopping a trial early for that reason can save a company money and time that would otherwise be spent on a study unlikely to succeed, but it also removes a potential source of future growth, which can weigh on the stock.

What a Monitoring Committee Does

Large clinical trials are overseen by independent data monitoring committees, groups of experts who review results while a study is still running and can recommend stopping it early if a treatment is clearly working, raises safety concerns, or is unlikely to succeed.

In Geron's case, the committee's assessment was that the study was unlikely to show an improvement in overall survival, one of the most demanding and most valued goals a cancer trial can have.

What Geron Does

Geron is a commercial-stage biotech focused on blood cancers. Its drug imetelstat, a telomerase inhibitor, is sold under the brand name Rytelo for certain patients with lower-risk myelodysplastic syndromes, a group of disorders in which the bone marrow does not produce enough healthy blood cells.

The company has been studying imetelstat in other blood cancers to expand its use, and the discontinued trial was part of that wider development effort.